Ignite Creation Date:
2024-05-05 @ 11:55 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01455688
Status:
COMPLETED
Last Update Posted:
2018-04-12
First Post:
2011-10-17
Brief Title:
Early Antiviral Therapy for Critically Ill HIV Infected Patients
Sponsor:
Hospital Nossa Senhora da Conceicao
Organization:
Hospital Nossa Senhora da Conceicao
Study Overview
Official Title:
Early Antiretroviral Therapy for Critically Ill HIV Infected Patients
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to verify the effect of HAART in critically ill HIV infected patients The current practice is to begin antiviral therapy after ICU discharge when the condition of the patient is more stable The investigators hypothesis is that the investigators can improve outcome of these patients with earlier antiviral therapy in the ICU The investigators just have retrospective studies in this scenario After admission to ICU patients are assigned to one of two arms early HAART within 5 days of ICU admission or conventional therapy initiation of HAART after ICU discharge The following data will be collected demographic variables CD4 count viral load drug toxicity opportunistic infection hemodialysis mechanical ventilation and vasoactive drug The patients will be followed to determine ICU mortality hospital mortality and 6-month mortality
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None